FY2026 Earnings Estimate for Accuray Issued By Roth Capital

Accuray Incorporated (NASDAQ:ARAY) – Investment analysts at Roth Capital raised their FY2026 EPS estimates for Accuray in a research note issued to investors on Tuesday, November 19th. Roth Capital analyst J. Wittes now forecasts that the medical equipment provider will earn $0.11 per share for the year, up from their prior estimate of $0.08. The consensus estimate for Accuray’s current full-year earnings is $0.01 per share.

Separately, StockNews.com cut shares of Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Stock Up 3.0 %

ARAY stock opened at $1.89 on Friday. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. Accuray has a 52-week low of $1.40 and a 52-week high of $3.05. The company has a 50-day moving average of $1.85 and a two-hundred day moving average of $1.83. The stock has a market capitalization of $189.57 million, a price-to-earnings ratio of -11.09 and a beta of 1.40.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The firm had revenue of $101.55 million during the quarter, compared to analysts’ expectations of $98.10 million. During the same period in the prior year, the company posted ($0.03) earnings per share.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its position in shares of Accuray by 0.3% during the second quarter. Renaissance Technologies LLC now owns 2,812,184 shares of the medical equipment provider’s stock valued at $5,118,000 after buying an additional 7,500 shares during the last quarter. Foundry Partners LLC raised its position in shares of Accuray by 51.3% during the third quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after buying an additional 741,900 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Accuray by 2.1% during the third quarter. Geode Capital Management LLC now owns 2,179,396 shares of the medical equipment provider’s stock valued at $3,924,000 after buying an additional 45,548 shares during the last quarter. State Street Corp raised its position in shares of Accuray by 3.8% during the third quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock valued at $3,410,000 after buying an additional 70,008 shares during the last quarter. Finally, FMR LLC raised its position in shares of Accuray by 27.2% during the third quarter. FMR LLC now owns 582,591 shares of the medical equipment provider’s stock valued at $1,049,000 after buying an additional 124,459 shares during the last quarter. Institutional investors and hedge funds own 64.08% of the company’s stock.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.